JW Holdings Corp is a Korea-based company principally engaged in the production and sale of pharmaceuticals. The Company is principally engaged in the production and sale of pharmaceuticals such as antibiotics, antifungal agents, blood and body fluids substitutes, hyperlipidemia drugs, electrolyte additives, angina pills and digestive medicines. The Company is also engaged in the manufacture and sale of diagnostic equipment for hematology, immunology and others. In addition, the Company is engaged in the holding businesses.

Employees

114

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	₩3,665.00	+0.96%	102,147
05/11/26	₩3,630.00	-6.56%	173,724
04/11/26	₩3,885.00	+1.57%	158,805
03/11/26	₩3,825.00	-1.42%	62,710
02/11/26	₩3,880.00	-2.14%	43,957

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 06/11/2026			5-day change	1st Jan Change
3,665.00 ^KRW	+0.96%		-7.57%	+2.09%

08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	254B 186M 167M 152M 139M 262M 17.48B 270M 1.84B 733M 9.33B 698M 683M 29.45B	P/E 2024	3.45x	P/E 2025	4.27x
Enterprise Value	524B 384M 344M 315M 287M 541M 36.1B 558M 3.79B 1.51B 19.26B 1.44B 1.41B 60.81B	EV / Sales 2024	0.65x	EV / Sales 2025	0.53x
Free-Float	39.41%	Yield 2024	5.13%	Yield 2025	5.99%

08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-05	JW Holdings Corporation announces Annual dividend, payable on April 24, 2026	CI
11-14	JW Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-03	Jw Holdings Q3 operating profit 5 billion won, up 38.4% from year earlier	RE
14/08/25	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
31/07/25	Jw Holdings Q2 operating profit 3.4 billion won, down 82% from year earlier	RE
04/07/25	Sound Smithy Co Ltd announced that it has received KRW 200 million in funding from JW Holdings Corporation	CI
26/06/25	Sound Smithy Co Ltd announced that it expects to receive KRW 200 million in funding from JW Holdings Corporation	CI
25/06/25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
25/06/25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
24/06/25	JW Holdings Corporation's Equity Buyback announced on March 24, 2025 has expired with 714,439 shares, representing 1.02% for KRW 2,500 million.	CI

04/10/23	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Mercredi 4 octobre 2023
04/10/23	Kering : Seán McGirr nommé Directeur de la Création d'Alexander McQueen
03/10/23	Kering : nouveau directeur création chez Alexander McQueen
03/10/23	Kering nomme Seán McGirr directeur de la création chez Alexander McQueen
18/08/23	El Kospi de Corea cae un 0,6%, su mayor racha de pérdidas desde junio de 2022 -- Market Talk

JW Holdings Corporation Stock

Stocks

A096760

KR7096760004

Pharmaceuticals

Valuation: JW Holdings Corporation

Chart: JW Holdings Corporation

Latest news: JW Holdings Corporation

News in other languages: JW Holdings Corporation

Quotes and Performance

Price Extremes

Managers and Directors: JW Holdings Corporation

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+0.96%
1 week	-7.57%
Current month	-7.57%
1 month	-13.36%
3 months	-6.51%
6 months	-11.04%
Current year	+2.09%

1 week	3,530	4,000
1 month	3,530	4,190
Current year	3,300	4,720
1 year	3,300	4,720
3 years	2,650	4,720
5 years	2,536.65	4,720
10 years	2,536.65	9,991.64

Manager	Title	Age	Since
Seong-Nam Cha CEO	Chief Executive Officer	69	27/03/2024
Kyung-Ha Lee CEO	Chief Executive Officer	63	-
Ji-Woo Choi DFI	Director of Finance/CFO	60	27/03/2020

Director	Title	Age	Since
Kyung-Ha Lee CHM	Chairman	63	-
Chan-Yeop Yeom BRD	Director/Board Member	64	27/03/2020
Ji-Woo Choi BRD	Director/Board Member	60	27/03/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
07/02/24	Sung-Kweon Han	Free	Chief Executive Officer	215	0.0003%
07/02/24	Gui-eung Song	Free		4	0.0000%	-
07/02/24	Kyung-Ha Lee	Free	Chief Executive Officer	412,069	0.5574%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JW HOLDINGS CORPORATION	+0.96%	-7.57%	+7.64%	+9.15%	186M
ELI LILLY AND COMPANY	-0.79%	-4.48%	+46.48%	+118.69%	1,206B
JOHNSON & JOHNSON	+1.43%	+1.11%	+48.05%	+83.72%	665B
ABBVIE INC.	+1.07%	-1.21%	+32.92%	+105.10%	515B
ROCHE HOLDING AG	-0.36%	-3.25%	+45.42%	+65.10%	381B
MERCK & CO., INC.	-0.14%	-1.87%	+70.06%	+40.55%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.47%	+58.09%	307B
ASTRAZENECA PLC	-0.80%	-0.21%	+7.98%	+36.17%	289B
AMGEN INC.	+0.03%	-1.20%	+43.79%	+68.49%	249B
GILEAD SCIENCES, INC.	-0.41%	-2.22%	+40.43%	+114.24%	207B
Average	+0.02%	-1.94%	+37.32%	+69.93%	417.99B
Weighted average by Cap.	-0.04%	-1.96%	+42.71%	+86.45%

	2024	2025
Net sales	888B 651M 584M 534M 487M 918M 61.19B 947M 6.43B 2.56B 32.65B 2.44B 2.39B 103B	970B 711M 638M 583M 532M 1B 66.84B 1.03B 7.02B 2.8B 35.66B 2.67B 2.61B 113B
Net income	62.62B 45.92M 41.18M 37.64M 34.36M 64.73M 4.32B 66.77M 454M 181M 2.3B 172M 169M 7.27B	58.5B 42.9M 38.48M 35.17M 32.1M 60.48M 4.03B 62.39M 424M 169M 2.15B 161M 158M 6.79B
Net Debt	362B 265M 238M 217M 198M 374M 24.93B 386M 2.62B 1.04B 13.3B 996M 974M 42B	270B 198M 178M 162M 148M 279M 18.62B 288M 1.96B 780M 9.93B 743M 727M 31.36B